srt-2104 srt-2104 srt-2104 is an experimental drug that was studied by sirtris pharmaceuticals as a small-molecule activator of the sirtuin subtype sirt1. the compound progressed to phase ii human trials for type ii diabetes before development was discontinued, however it continues to be widely used in animal research into the functions of sirt1. srt-2104identifiers iupac name 4-methyl-n-thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide cas number1093403-33-8pubchem cid25108829drugbankdb12186 ychemspider28637794unii4521nr0j09chemblchembl4297436comptox dashboard (epa)dtxsid00648729 chemical and physical dataformulac26h24n6o2s2molar mass516.64 g·mol−13d model (jsmol)interactive image smiles cc1=c(sc(=n1)c2=cn=cc=c2)c(=o)nc3=cc=cc=c3c4=cn5c(=csc5=n4)cn6ccocc6 inchi inchi=1s/c26h24n6o2s2/c1-17-23(36-25(28-17)18-5-4-8-27-13-18)24(33)29-21-7-3-2-6-20(21)22-15-32-19(16-35-26(32)30-22)14-31-9-11-34-12-10-31/h2-8,13,15-16h,9-12,14h2,1h3,(h,29,33)key:lamqviqmvkwxoc-uhfffaoysa-n